Active, not recruitingPHASE2, PHASE3NCT03952585
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Studying Squamous cell carcinoma of the oropharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sue S Yom, M.D., Ph.DNRG Oncology
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 384 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- PCR Oncology, Arroyo Grande, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente Dublin, Dublin, California, United States
- UC San Diego Health System - Encinitas, Encinitas, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03952585 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the oropharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06915038ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the OropharynxIndiana University
- RECRUITINGPHASE1NCT06747390Intratumoral Lidocaine Injection Before Oropharyngeal Cancer SurgeryRyan Carey
- RECRUITINGPHASE2NCT06702033The Minimalist Trial-2Washington University School of Medicine
- RECRUITINGPHASE1NCT06589609Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal CancerBlueSky Immunotherapies GmbH
- RECRUITINGPHASE2NCT06223568Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05582122SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal CancersUNICANCER
- ACTIVE NOT RECRUITINGNCT06592716Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?Rigshospitalet, Denmark
- RECRUITINGPHASE2NCT06323460Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerOhio State University Comprehensive Cancer Center
See all trials for Squamous cell carcinoma of the oropharynx →